This marks the fourth consecutive year Alexandria has received this impactful recognition, which ranks the company as the second most trustworthy among the twenty-two listed within the real estate and housing category for 2026, and further underscores its longstanding leadership as the most trusted brand in life science real estate.
Newsweek’s prestigious annual list, which was compiled in collaboration with the publication’s market research partner Statista, is based on an extensive independent survey of 25,000 U.S. residents who submitted 101,000 company evaluations across three key touchpoints of trust: customer, investor, and employee, as well as an analysis of online media sentiment.
“We are honored and humbled to receive multiyear recognition as one of the Most Trustworthy Companies in America by Newsweek, which reinforces our positive consequential impact as a mission-driven company at the heart and vanguard of the life science industry. As is often attributed to Aristotle, ‘Excellence is never an accident. It is the result of high intention, sincere effort and intelligent execution.’ Through the operational excellence of our best-in-class team and their pivotal support of our tenants’ mission-critical work, we are a key part of the engine that drives life-changing innovation. Since 2013, 49% of FDA approvals have been developed by Alexandria tenants,” said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. “As the pioneer of life science real estate, our one-of-a-kind ability to develop longstanding trusted relationships with top life science companies and our strategic leadership in creating long-term value for our investors are central to our distinctive business model.”
Led by a seasoned, long-tenured management team that has successfully navigated multiple market cycles, the company continues to have a strong and flexible balance sheet with significant liquidity, and high-quality cash flows from a diverse mix of tenants, with 53% of its annual rental revenue from investment-grade or large-cap tenants, as of December 31, 2025. Creating long-term value for investors and aligning with their interests have been consequential to Alexandria’s corporate strategy since its initial public offering in 1997.
Alexandria has strategically cultivated trusted relationships with leading life science entities, including Eli Lilly, Bristol Myers Squibb and Novartis. 82% of the company’s 2025 leasing activity was generated from its deep pool of existing tenants. In February 2026, Alexandria broke ground on a 466,598 RSF Biomedical Research Center at the Campus Point Megacampus in San Diego for leading pharmaceutical company and longstanding tenant Novartis. The state-of-the-art facility will be a new innovation center for the development of breakthrough treatments, and will feature data and computational capabilities and advanced artificial intelligence. This long-term lease underscores the industry’s trust in the Alexandria brand; its design, development and operations prowess; and the strategic value of the Megacampus platform.
Alexandria’s highly differentiated Megacampus ecosystems, which represent 78% of its annual rental revenue, as of December 31, 2025, deliver irreplaceable assets clustered in unmatched locations, intentionally designed to fuel the critical drivers for scientific innovation; they foster collaboration and tenant well-being, and strengthen the recruitment and retention of top talent.
As a multiyear recipient of Newsweek’s Most Trusted Companies in America recognition and recent naming on the inaugural Most Charitable Companies in America list by Newsweek (March 2026), Alexandria continues to distinguish itself through its unwavering commitment to integrity, long-term value creation, and positive societal impact. The company remains steadfast in its mission to create and grow ecosystems that advance human health while strengthening the communities in which its employees and tenants live and work.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of December 31, 2025, Alexandria has a total market capitalization of $20.75 billion and an asset base in North America that includes 35.9 million RSF of operating properties. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants’ ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria’s impact on the development of novel medicines, treatments, therapies, and cures and on human health and well-being; Alexandria’s thought leadership, collaborations, investments, and progress relating to the treatment of depression; the launch, goals, and efforts of the MAP-D program; the likelihood of continued commitment and efforts by Alexandria to foster collaboration that improves human health; and Alexandria’s ability to meet and anticipate industry needs and maintain strategic relationships. These forward-looking statements are based on Alexandria’s present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria’s forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria’s forward-looking statements, and risks and uncertainties to Alexandria’s business in general, please refer to Alexandria’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Paula Schwartz, Managing Director, Rx Communications Group, (917) 633-7790, [email protected]
SOURCE Alexandria Real Estate Equities, Inc.